Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofol vs remimazolam vs remimazolam + flumazenil for recovery from general anesthesia in gynecological ambulatory surgery
ChiCTR2600122589Phase 4Not yet recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in well-being comparing Group C (ciprofol), Group RS (remimazolam + saline) and Group RF (remimazolam + flumazenil) (3 arms). Primary endpoint: Time from discontinuation of drug administration to eye opening. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ciprofolremimazolamflumazenil
03
Conditions
well-being
Beyond the preview
Go deeper on ChiCTR2600122589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122589.